Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human
InventorsSabina A. Kratzmeier, Rosandra N. Kaplan, Cristina Contreras Burrola, Catherine Hedrick, Ahmad Alimadadi
Estimating the term…
The invention provides a method for predicting the susceptibility of a patient suffering from a cancer or a myeloid-mediated disease to immunotherapy. Furthermore, the invention provides a method for treating a patient suffering from a cancer or a myeloid-mediated disease with immunotherapy. In accordance with these embodiments, the inventive method includes assaying myeloid cells obtained from the patient prior to treatment for the expression of CXCR3. The invention also provides a genetically engineered myeloid cell (GEMy) in which the expression of CXCR3 is modulated (up- or down-regulated). The invention further provides a composition comprising the inventive GEMy and a pharmaceutically acceptable carrier. The invention also provides a method for treating a patient in need of immunotherapy comprising administering the inventive composition to a patient.
A method for predicting the susceptibility of a patient suffering from a cancer or a myeloid-mediated disease to immunotherapy, the method comprising
A method for treating a patient suffering from a cancer or a myeloid-mediated disease with cell-based immunotherapy, the method comprising
A GEMy cell comprising a myeloid cell comprising an exogenous genetic expression construct comprising a nucleic sequence encoding a CXCR3 protein.
(canceled)
A GEMy cell comprising a myeloid cell genetically modified to reduce or eliminate production of a CXCR3 protein.
25-56. (canceled)
Dependencies are inferred from the claim text.